Navigation Links
New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
Date:7/6/2009

LEIDEN, The Netherlands, July 6 /PRNewswire/ -- Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget of nearly 6 million euros.

The new consortium, formed by Syncom, Synvolux Therapeutics, and University Medical Center Groningen, focuses on designing a versatile drug delivery system for inflammatory diseases and cancer. Another new consortium is formed by InteRNA Technologies, Utrecht University and VU University Medical Center, and focuses on the development of anti-angiogenic microRNA-based therapeutic products for the treatment of cancer.

Versatile drug delivery platform for inflammatory diseases and cancer

New molecular entities (NMEs) in the drug development pipeline comprise various classes of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulation might circumvent side effects and improve their general therapeutic efficacy. However, currently, no appropriate formulation technology is available for these kinase inhibitors.

This project focuses on a systematic approach in which chemical modification of NMEs is combined with drug formulation studies. This will lead to a versatile drug delivery platform for future clinical application of kinase inhibitors in the treatment of cancer and chronic inflammatory diseases. "This approach is expected to make targeted drug delivery finally meet its expectations, as it will become available for a variety of drug classes that are under development in the pharmaceutical industry," according to the consortium members.

Development of novel anti-angiogenic miRNA based therapeutics

"Conventional cancer treatment such as surgery, radiation therapy and chemotherapy are far from sufficient, therefore, new strategies of cancer treatment are needed more than ever," says Roel Schaapveld, Chief Executive Officer, InteRNA. There is a large body of evidence indicating that tumor growth and metastasis formation are dependent on the formation of new blood vessels. Furthermore, angiogenesis is an early event in the development of tumors, being already switched on in pre-cancerous events and long before visible or clinically relevant tumor mass is present. Schaapveld: "These two features make angiogenesis an ideal target for the development of novel anti-cancer strategies."

The recent discovery that non-coding RNAs, called microRNAs (miRNAs), play a critical role in gene regulation provides new opportunities to discover RNAs that can control angiogenesis. The major aim of this project is to establish a technology platform for the development of (anti-cancer) therapeutics based on angiostatic miRNAs. miRNA is utilized as a therapeutic modality and advanced nanoparticle delivery systems accomplish intracellular delivery of nucleic acid agents. These will be combined with the identification of surface receptor targets on tumor blood vessels to allow for therapeutic intervention. Eventually, this will result in the development of anti-angiogenic miRNA-based therapeutic products for the treatment of cancer.


'/>"/>
SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
2. Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)
3. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
4. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
7. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
9. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
10. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
11. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):